ATE426389T1 - Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische - Google Patents
Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemischeInfo
- Publication number
- ATE426389T1 ATE426389T1 AT02804079T AT02804079T ATE426389T1 AT E426389 T1 ATE426389 T1 AT E426389T1 AT 02804079 T AT02804079 T AT 02804079T AT 02804079 T AT02804079 T AT 02804079T AT E426389 T1 ATE426389 T1 AT E426389T1
- Authority
- AT
- Austria
- Prior art keywords
- theaflavin
- gallate
- digallate
- mixtures
- production
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
- C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
- C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
- C07D311/60—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2
- C07D311/62—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with aryl radicals attached in position 2 with oxygen atoms directly attached in position 3, e.g. anthocyanidins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Virology (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33351501P | 2001-11-28 | 2001-11-28 | |
CNB021115125A CN1156276C (zh) | 2002-04-26 | 2002-04-26 | 茶黄素的新用途 |
US41357602P | 2002-09-24 | 2002-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE426389T1 true ATE426389T1 (de) | 2009-04-15 |
Family
ID=27178819
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT02804079T ATE426389T1 (de) | 2001-11-28 | 2002-11-27 | Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische |
Country Status (10)
Country | Link |
---|---|
EP (1) | EP1460999B1 (de) |
JP (1) | JP2005523242A (de) |
KR (1) | KR20080052675A (de) |
AT (1) | ATE426389T1 (de) |
AU (1) | AU2002365415C1 (de) |
CA (1) | CA2467664A1 (de) |
DE (1) | DE60231747D1 (de) |
MX (1) | MXPA04005113A (de) |
NZ (2) | NZ533190A (de) |
WO (1) | WO2003045328A2 (de) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4903436B2 (ja) * | 2004-02-17 | 2012-03-28 | サントリーホールディングス株式会社 | 高分子ポリフェノール画分を含有するリパーゼ活性阻害剤、茶エキス、およびその製造方法 |
JP5242885B2 (ja) * | 2004-05-20 | 2013-07-24 | 株式会社 伊藤園 | 筋肉内ampk活性化剤 |
JP5159108B2 (ja) * | 2004-07-05 | 2013-03-06 | サントリーホールディングス株式会社 | リパーゼ阻害剤 |
JP4880965B2 (ja) * | 2005-10-03 | 2012-02-22 | 株式会社ヤクルト本社 | 抗脂肪性薬剤 |
WO2007125644A1 (ja) | 2006-04-26 | 2007-11-08 | Ito En, Ltd. | 脂質吸収阻害剤 |
JP5441046B2 (ja) * | 2006-05-01 | 2014-03-12 | 国立大学法人 筑波大学 | 脂肪肝の予防および/または治療剤 |
WO2009119111A1 (ja) * | 2008-03-28 | 2009-10-01 | 静岡県公立大学法人 | 生茶葉を用いたテアフラビン類の製造方法 |
JP2010095477A (ja) * | 2008-10-17 | 2010-04-30 | Ito En Ltd | リパーゼ阻害剤 |
JP2010095478A (ja) * | 2008-10-17 | 2010-04-30 | Ito En Ltd | 体脂肪蓄積抑制剤及び飲食品 |
JP5614674B2 (ja) * | 2009-09-18 | 2014-10-29 | 万壽美 竹元 | 生活習慣病予防及び改善剤 |
JP2012072084A (ja) * | 2010-09-29 | 2012-04-12 | Kracie Home Products Ltd | エラスターゼ阻害剤並びにそれを含有する化粧品組成物及び医薬品組成物 |
CN103103227A (zh) * | 2013-01-18 | 2013-05-15 | 徐州医学院 | 一种具有α-葡萄糖苷酶抑制作用的茶多酚氧化聚合物的制备工艺 |
JP6478368B2 (ja) * | 2013-12-26 | 2019-03-06 | 大塚食品株式会社 | テアフラビン類の製造方法、及びテアフラビン類を含む飲料 |
JP6514684B2 (ja) * | 2014-03-27 | 2019-05-15 | 焼津水産化学工業株式会社 | 口腔内細菌増殖抑制剤 |
US9957245B2 (en) | 2014-06-27 | 2018-05-01 | Nbc Meshtec Inc. | Catalyst for synthesizing theaflavins and method for synthesizing theaflavins |
CN106511362B (zh) * | 2015-09-15 | 2020-11-17 | 广东省人民医院 | 一种防治动脉粥样硬化的茶多酚组合物 |
JP6778506B2 (ja) * | 2016-04-21 | 2020-11-04 | 焼津水産化学工業株式会社 | 機能性食品組成物 |
KR102359446B1 (ko) | 2019-04-25 | 2022-02-09 | (주)아모레퍼시픽 | 테아플라빈을 포함하는 지방세포 분화 촉진용 조성물 |
WO2020218755A1 (ko) * | 2019-04-25 | 2020-10-29 | ㈜아모레퍼시픽 | 테아플라빈을 포함하는 지방세포 분화 촉진용 조성물 |
CN114533723A (zh) * | 2022-01-19 | 2022-05-27 | 湖南农业大学 | 一种调节骨骼肌糖代谢与线粒体生成的膳食营养补充剂及其应用 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2975057A (en) * | 1958-05-23 | 1961-03-14 | Lipton Inc Thomas J | Process for converting green tea extract |
CH570772A5 (de) * | 1972-01-31 | 1975-12-31 | Unilever Nv | |
JPS63214183A (ja) * | 1987-03-03 | 1988-09-06 | Mitsui Norin Kk | アンジオテンシン1変換酵素阻害剤 |
US5318986A (en) * | 1989-10-19 | 1994-06-07 | Mitsui Norin Co., Ltd. | Method of inhibiting the activity of α-amylase |
JP3018013B2 (ja) * | 1989-10-19 | 2000-03-13 | 三井農林株式会社 | α―アミラーゼ活性阻害剤 |
CN1035660C (zh) * | 1993-01-01 | 1997-08-20 | 江西省绿色工业(集团)公司 | 茶色素及其生产方法 |
JP4127863B2 (ja) * | 1993-03-04 | 2008-07-30 | 太陽化学株式会社 | 腸内環境改善組成物 |
DE69611770T2 (de) * | 1995-09-04 | 2001-05-31 | Unilever N.V., Rotterdam | Verfahren zur Farbvertiefung in Nahrungsmitteln auf Teebasis |
DE19627344A1 (de) * | 1996-07-01 | 1998-01-08 | Vitasyn Gmbh Entwicklung & Ver | Therapeutisch wirksame bzw. gesundheitsfördernde Zubereitung aus definierten Polyphenolverbindungen |
JPH1132725A (ja) * | 1997-07-24 | 1999-02-09 | Mitsui Norin Kk | 流動食 |
JP2000327572A (ja) * | 1999-05-18 | 2000-11-28 | Mitsui Norin Co Ltd | スクアレンエポキシダーゼ阻害剤 |
CN1328092A (zh) * | 2000-06-08 | 2001-12-26 | 陈虎 | 一种新的提取茶色素的方法及其在高血脂方面的应用 |
-
2002
- 2002-11-27 EP EP02804079A patent/EP1460999B1/de not_active Expired - Lifetime
- 2002-11-27 MX MXPA04005113A patent/MXPA04005113A/es active IP Right Grant
- 2002-11-27 NZ NZ533190A patent/NZ533190A/en not_active IP Right Cessation
- 2002-11-27 KR KR1020087009558A patent/KR20080052675A/ko not_active Application Discontinuation
- 2002-11-27 JP JP2003546833A patent/JP2005523242A/ja active Pending
- 2002-11-27 NZ NZ569389A patent/NZ569389A/en not_active IP Right Cessation
- 2002-11-27 CA CA002467664A patent/CA2467664A1/en not_active Abandoned
- 2002-11-27 AT AT02804079T patent/ATE426389T1/de not_active IP Right Cessation
- 2002-11-27 AU AU2002365415A patent/AU2002365415C1/en not_active Expired
- 2002-11-27 DE DE60231747T patent/DE60231747D1/de not_active Expired - Lifetime
- 2002-11-27 WO PCT/US2002/038177 patent/WO2003045328A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
CA2467664A1 (en) | 2003-06-05 |
KR20080052675A (ko) | 2008-06-11 |
DE60231747D1 (de) | 2009-05-07 |
JP2005523242A (ja) | 2005-08-04 |
NZ533190A (en) | 2008-07-31 |
WO2003045328A3 (en) | 2003-10-09 |
AU2002365415C1 (en) | 2008-12-11 |
EP1460999A4 (de) | 2005-03-09 |
EP1460999A2 (de) | 2004-09-29 |
MXPA04005113A (es) | 2005-04-29 |
WO2003045328A2 (en) | 2003-06-05 |
NZ569389A (en) | 2010-01-29 |
AU2002365415B2 (en) | 2008-04-10 |
AU2002365415A1 (en) | 2003-06-10 |
EP1460999B1 (de) | 2009-03-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE426389T1 (de) | Verfahren zur herstellung und verwendung von theaflavin, theaflavin-3-gallat, theaflavin-3'- gallat und theaflavin 3,3'-digallat und ihrer gemische | |
WO2004112715A3 (en) | Methods of making and using theaflavin,theaflavin-3-gallate, theaflavin-3’-gallate and theaflavin 3,3’ - digallate and mixtures thereof | |
BG66103B1 (bg) | Кондензирани пиролокарбазоли | |
BG105177A (en) | Novel substituted pyrazole derivatives | |
IL110031A0 (en) | Phenyl heterocycles, their manufacture and pharmaceutical compositions containing them | |
IL143402A0 (en) | Fused 1,2,4-thiadiazine derivatives, their preparation and use | |
BG103740A (en) | Phytostyrene composition for the prevention of the alzheimer's disease | |
SG158731A1 (en) | Novel medicament compositions, based on anticholinergically effective compounds and beta-mimetics | |
ES2142570T3 (es) | Bisesteres de acido alqu(en)ildicarboxilico, su empleo, asi como procedimientos para su obtencion. | |
WO2004043954A3 (en) | Trans-9,10-dehydroepothilone c and d, analogs thereof and methos of making the same | |
ATE471924T1 (de) | 3-alkyl-5,5',6,6',7,7',8,8'-octahydro-2,2'- binaphthole und 3,3'-dialkyl-5,5',6,6',7,7',8,8'- octahydro-2,2'-binaphthole, sowie verfahren zur ihrer herstellung | |
WO2000021910A3 (en) | 1,2-disubstituted cyclopropanes | |
IL160171A0 (en) | Depsipeptide derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same | |
SG149042A1 (en) | Novel fused pyrrolocarbazoles | |
MXPA04002282A (es) | Nuevos compuestos y preparaciones como inhibidores de la catepsina. | |
DE69121502D1 (de) | Prozess zur darstellung von aspartam aus einem diketopiperazin sowie neue zwischenprodukte und derivate dafür | |
TW200420294A (en) | Methods of making and using theaflavin, thealflavin-3-gallate, theaflavin-3'-gallate and theaflavin 3, 3'-digallate and mixtures thereof | |
HK1018265A1 (en) | Piperazino derivatives as neurokinin antagonists | |
DE69927602D1 (de) | Verfahren zur herstellung von vitaminpulvern | |
MX9708416A (es) | Derivados de piperazino como antagonistas de neuroquininas. | |
DE69901519D1 (de) | Verfahren zur Herstellung von 2,2'-bis (Hydroxymethyl)alkansäure | |
DE60123105D1 (de) | Verfahren zur Herstellung von 4'-O-substituierten 4'-Demethyl-1 desoxypodophyllotoxinderivaten und geometrischen Isomeren davon ,und Antikrebspräparat, das diese enthält | |
MX337902B (es) | Metodos para hacer y utilizar teaflavin, teafavlin-3-galato, teaflavin-3'-galato y teaflavin 3,3´-digalato y mezclas de las mismas. | |
AU2002254930A1 (en) | Novel medicament compositions based on anticholinergic agents and endothelin antagonists | |
DE50006244D1 (en) | Neue substituierte 3-phenoxy- und 3-phenylalkyloxy-2-phenyl-propylamine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |